148 related articles for article (PubMed ID: 16207681)
1. Folate during antifolate chemotherapy: what we know... and do not know.
Robien K
Nutr Clin Pract; 2005 Aug; 20(4):411-22. PubMed ID: 16207681
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
3. Folate, folic acid, and chemotherapy-induced toxicities: A systematic literature review.
Zwart NRK; Franken MD; Tissing WJE; Lubberman FJE; McKay JA; Kampman E; Kok DE
Crit Rev Oncol Hematol; 2023 Aug; 188():104061. PubMed ID: 37353179
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies targeting proteins that regulate folate and reduced folate transport.
Trippett TM; Bertino JR
J Chemother; 1999 Feb; 11(1):3-10. PubMed ID: 10078775
[TBL] [Abstract][Full Text] [Related]
5. Folate and antifolate pharmacology.
Kamen B
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-30-S18-39. PubMed ID: 9420019
[TBL] [Abstract][Full Text] [Related]
6. Folate, antifolates, and folate analogs in pediatric oncology.
Hum MC; Kamen BA
Invest New Drugs; 1996; 14(1):101-11. PubMed ID: 8880397
[No Abstract] [Full Text] [Related]
7. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
8. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.
Gonen N; Assaraf YG
Drug Resist Updat; 2012 Aug; 15(4):183-210. PubMed ID: 22921318
[TBL] [Abstract][Full Text] [Related]
9. Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update.
Synold TW; Willits EM; Barredo JC
Leuk Lymphoma; 1996 Mar; 21(1-2):9-15. PubMed ID: 8907263
[TBL] [Abstract][Full Text] [Related]
10. The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Goldman ID; Chattopadhyay S; Zhao R; Moran R
Curr Opin Investig Drugs; 2010 Dec; 11(12):1409-23. PubMed ID: 21154123
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid.
Alati T; Worzalla JF; Shih C; Bewley JR; Lewis S; Moran RG; Grindey GB
Cancer Res; 1996 May; 56(10):2331-5. PubMed ID: 8625328
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed safety and dosing strategy.
Niyikiza C; Hanauske AR; Rusthoven JJ; Calvert AH; Allen R; Paoletti P; Bunn PA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):24-9. PubMed ID: 12571807
[TBL] [Abstract][Full Text] [Related]
13. [Folate antagonist].
Morikawa N
Nihon Rinsho; 2015 Feb; 73 Suppl 2():146-8. PubMed ID: 25831740
[No Abstract] [Full Text] [Related]
14. Folate supplementation during methotrexate therapy for rheumatoid arthritis.
Morgan SL; Baggott JE
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S102-9. PubMed ID: 21044441
[TBL] [Abstract][Full Text] [Related]
15. The impact of folate status on the efficacy of colorectal cancer treatment.
Porcelli L; Assaraf YG; Azzariti A; Paradiso A; Jansen G; Peters GJ
Curr Drug Metab; 2011 Dec; 12(10):975-84. PubMed ID: 21787267
[TBL] [Abstract][Full Text] [Related]
16. Potential effects of dietary folate supplementation on oral carcinogenesis, development and progression.
Kingsley K
J Diet Suppl; 2010 Mar; 7(1):51-9. PubMed ID: 22435573
[TBL] [Abstract][Full Text] [Related]
17. 5-Methyltetrahydrohomofolate.
O'Dwyer PJ; Wagner BH; Hoth DF; Leyland-Jones B
Invest New Drugs; 1987; 5(3):215-8. PubMed ID: 3312079
[TBL] [Abstract][Full Text] [Related]
18. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
19. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.
Pakakasama S; Kanchanakamhaeng K; Kajanachumpol S; Udomsubpayakul U; Sirachainan N; Thithapandha A; Hongeng S
Ann Hematol; 2007 Aug; 86(8):609-11. PubMed ID: 17323057
[No Abstract] [Full Text] [Related]
20. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
Chattopadhyay S; Tamari R; Min SH; Zhao R; Tsai E; Goldman ID
Oncologist; 2007 Jul; 12(7):808-15. PubMed ID: 17673612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
